Metabolite Of Thyrotropin-releasing Hormone Research Articles

TRH microdialysis into the RTN of the conscious rat increases breathing, metabolism, and temperature.

Thyrotropin-releasing hormone (TRH) injected into the retrotrapezoid nucleus (RTN) of anesthetized rats produces a large, prolonged stimulation of ventilatory output (C. L. Cream, A. Li, and E. E. Nattie. J. Appl. Physiol. 83: 792-799, 1997). Here we inject or dialyze TRH into the RTN of conscious rats. In 6 of 17 injections (200 nl, 3.1 +/- 1.7 mM), ventilation (VE) increased 31% by 10 min, with recovery by 60 min. With dialysis, each animal of one group (n = 5) received, in random order, 10 mM TRH, 10 mM TRHOH (a metabolite of TRH), and artificial cerebrospinal fluid (aCSF); each animal of a second group (n = 5) received aCSF and 1 mM TRH. TRHOH and aCSF had no sustained effects. TRH (1 mM) increased VE (32%, P < 0.02, by 10 min, with recovery by 60 min), O(2) consumption (VO(2); 19%, P < 0. 03), and body (rectal) temperature (T(re); 0.5 degrees C, P < 0.09). TRH (10 mM) increased VE (78%, P < 0.01, by 10 min, with no recovery at 60 min), VO(2) (48%, P < 0.01), and T(re) (1.0 degrees C, P < 0. 01). TRH also induced arousal. The tissue volume affected in dialysis, estimated by spread of dialyzed fluorescein (332.3 mol wt, mol wt of TRH = 362.4), was 1,580 +/- 256 nl for 10 mM (n = 5) and 590 +/- 128 nl for 1 mM (n = 5). We conclude that 1) the RTN is involved in the integration of VE, VO(2), T(re), and arousal and 2) TRH may establish the responsiveness of RTN neurons.

Abundance of cyclo (His-Pro)-like immunoreactivity in the brain of TRH-deficient mice.

Cyclo(His-Pro) or CHP was initially discovered as a metabolite of thyrotropin-releasing hormone (TRH) resulting from the action of the enzyme Pyroglutamyl aminopeptidase. Physiologic and pharmacologic studies that followed this initial discovery provided indirect evidence that all CHP may not be derived from TRH. However, the recent availability of a TRH-deficient mouse has made it possible to reinvestigate whether CHP is derived from TRH. In the present study, we examined distribution of CHP and TRH in TRH-deficient mice. Northern blot analysis confirmed the absence of preproTRH mRNA in both the hypothalamus and the cortex of TRH-deficient mice. Brains from the wild-type and TRH-deficient mice were dissected into 7 regions, and TRH and CHP concentrations were determined by specific radioimmunoassay (RIA) in each region. Whereas TRH was identified in all regions of the wild-type brain, with the highest concentration in the hypothalamus, no detectable TRH was observed in any region in the TRH-deficient mice. While CHP-like immunoreactivity (CHP-LI) was present in all regions in the wild-type brain, its concentration was reduced by approximately 50% in the hypothalamus and cerebral cortex of TRH-deficient mice, with no change in other brain regions. Furthermore, the CHP-LI present in the brain of TRH-deficient mice was immunologically and chromatographically identical to synthetic CHP. These findings strongly suggest that a portion of the CHP in the brain is derived from sources other than TRH.

Cloning and Characterization of a New Subtype of Thyrotropin-Releasing Hormone Receptors

A new subfamily member of thyrotropin releasing hormone (TRH) receptor gene,TRHR2, was isolated from rat brain cDNAs. The deduced amino acid sequence ofTRHR2is 51 % identical to that of rat TRH receptor gene which was reported previously. Northern blot analysis withTRHR2probe revealed brain-specific expression of a 9.5 kb mRNA. In a binding experiment using the TRHR2-expressing COS cells, specific binding of TRH to TRHR2 was observed with Kd value of 9 nM which was equivalent to the Kd value (= 13 nM) of TRH binding to the TRH receptor previously reported. The active metabolite of TRH, histidyl-proline diketopiperazine, or cyclo(His-Pro), showed no specific binding activity. These results suggest that TRHR2 is a novel subtype of TRH receptor.

Enhancement by streptozotocin-induced diabetes of pancreatic prolyl endopeptidase activity in neonatal rats.

The effect of streptozotocin (STZ)-induced diabetes on the concentrations of deamidated TRH (TRH-OH), a metabolite of thyrotropin-releasing hormone (TRH) and prolyl endopeptidase (PE) activity were studied in the pancreas of neonatal rats to determine the contribution of beta-cells to PE activity and TRH-OH levels that we have previously found in this tissue. STZ treatment caused a significant reduction of immunoreactive TRH-OH levels on day-3 and -5 compared to untreated control rats. Reverse-phase high performance liquid chromatography of pooled extracts of 3-day-old normal rat pancreas revealed that about 50% of immunoreactive TRH-OH was found in the fractions representing authentic TRH-OH, whereas the remaining 50% eluted earlier. In STZ treated rats, all of the TRH-OH immunoreactive was associated with this early peak, no authentic TRH-OH could be detected. The specific activity of PE, on the other hand, rose 2.5-fold in diabetic 3-day-old pups (4.06 +/- 0.13 compared with 1.59 +/- 0.83 nmol/min/mg protein, P < 0.01, in controls). This increase declined with age (1.6- and 1.3-fold in 5 day- and 7-day-old pups, respectively). STZ treatment did not change pancreatic PE levels in 20-day-old rats control. Normalization of STZ induced hyperglycemia by sodium metavanadate treatment or by replacement of exogenous insulin did not restore pancreatic PE activity. The enhancement of PE activity following STZ treatment was specific for pancreas tissue. Furthermore, beta cytoxin drugs other than STZ that cause permanent diabetes such as alloxan enhanced PE activity to the same extend. Kinetic studies for PE activity show that Vmax is 3-fold higher in 3-day-old STZ-treated than in rat controls. In contrast, values for Km were comparable in rats of both groups (25 to 34 microM). We then tested whether the decrease of Vmax might have been caused by the presence of an PE inhibiting factor in these preparations. Gel-filtration experiments of pancreatic extracts revealed that the total apparent activity of eluted PE in 3-day-old control rats was 2-fold higher than in the original extract. In contrast, the recovery of eluted PE activity was not increased in the case of STZ-treated 3-day-old and untreated 20-day-old rats. These findings demonstrate that TRH-OH is identified in beta-cells and that an inhibiting factor(s) present in beta-cells appear(s) to be responsible for the unexpected enhancement of PE activity observed in STZ-treated neonatal rats.(ABSTRACT TRUNCATED AT 400 WORDS)

A study of the barium-sensitive and -insensitive components of the action of thyrotropin-releasing hormone on lumbar motoneurons of the rat isolated spinal cord.

The electrophysiological action of thyrotropin-releasing hormone (TRH) on rat spinal motoneurons was studied in vitro using single-electrode voltage- and current-clamp techniques. In current-clamp conditions TRH elicited a slowly developing depolarization, associated with a large input resistance increase and sustained neuronal firing; the primary metabolites of TRH were ineffective. Under voltage-clamp conditions in the presence of tetrodotoxin, TRH evoked a large inward current (ITRH; peaking at approximately -40 mV) associated with a large input conductance fall. Only 44% of cells displayed ITRH reversal; when the chord conductance values of these cells were plotted against membrane potential, a bell-shaped relation occurred, indicating voltage-dependent block by TRH of a persistent conductance active over a wide range of membrane potentials. ITRH reversal values were shifted to more positive levels in high K+ solution in Nernstian fashion; hence a large proportion of the TRH response is suggested to be mediated by the block of a K+ conductance (IK(T)). IK(T) (and its voltage-dependent block by TRH) was resistant to certain K+ channel antagonists (tetraethylammonium, Cs+, 4-aminopyridine or apamin), but was depressed by Ba2+. The Ba(2+)-resistant fraction of ITRH was attenuated by Cd2+, Mn2+ or Co2+, indicating that it probably involved a Ca(2+)-sensitive inward current. Concomitant application of Ba2+ and Cd2+ induced a near-total block of the response to TRH. It is suggested that suppression of IK(T), associated with the onset of a Ca(2+)-sensitive current, can explain the excitatory effect of TRH on rat spinal motoneurons.

Absorption of thyrotropin-releasing hormone (TRH) and a TRH prodrug in a human intestinal cell line (Caco-2)

The transepithelial transport of TRH and its prodrug ( N-octyloxycarbonyl) derivative was studied using the human colorectal carcinoma cell line Caco-2. No intact TRH prodrug was transported across the cells. Instead, TRH released from the prodrug was absorbed at rates comparable to those of labelled and unlabelled TRH. No metabolites of TRH could be detected. It can be concluded that the increased lipophilicity of the TRH prodrug is without effect on its transport characteristics.

Thyrotropin-releasing hormone facilitates display of reproductive behavior and locomotor behavior in an amphibian

In the amphibian brain, thyrotropin-releasing hormone (TRH) is present in many regions outside the hypothalamus. The functions of this extrahypothalamic TRH however are unknown. We sought to determine whether TRH or its metabolites altered reproductive behaviors (amplectic clasping behavior) or locomotor behaviors of the male South African clawed frog, Xenopus laevis. TRH-injected (100 μg; dorsal lymph sac injection) male Xenopus displayed significantly fewer amplectic clasp attempts and longer clasp durations than saline-injected controls. The TRH metabolites, TRH acid and histidylproline diketopiperazine, similarly altered clasping behavior. Several hormones released by TRH, including thyroid-stimulating hormone, melanocyte-stimulating hormone, prolactin, and dopamine, had no significant effect on clasp frequency or duration. Locomotor activity in Xenopus males was increased significantly after 15 min following TRH injection (150 μg); this effect persisted for at least 1 hr. The metabolites did not alter locomotion. These studies indicate that TRH can facilitate the display of two behaviors in the South African clawed frog. Effects of TRH on locomotor and reproductive behaviors thus appear in several vertebrate classes. These behavioral actions of TRH likely occur through different mechanisms or at different sites.

The effects of the TRH metabolite cyclo(His-Pro) and its analogs on feeding

Cyclo(His-Pro), or cHP, is a putative metabolite of thyrotropin-releasing hormone (TRH), and, like TRH, can inhibit food intake but requires higher doses. In attempts to improve the anorectic effects of cHP through modification of its structure, a number of its analogs were synthesized. These analogs or cHP itself were administered to rats either by intracerebroventricular (ICV) infusion or systemic injection, and their effects on food intake were measured. None of the synthetic analogs was more potent than cHP, although several analogs demonstrated comparable potencies to the parent compound. Interestingly, one cHP analog reversed the suppressive effect and stimulated feeding. This reversal, as well as the preservation of the anorectic effect by some but not all the analogs, suggests that the cHP effect on feeding does require specific structural features.

Lack of Effect of Histidyl-Proline Diketopiperazine on Basal Level and TRH-Induced Response of Cytosolic Calcium Concentration in Rat Lactotrophs.

Histidyl-proline diketopiperazine [cyclo(His-Pro)] has recently been shown to inhibit prolactin (PRL) secretion in vitro and in vivo. This peptide is well known as a metabolite of thyrotropin-releasing hormone (TRH), which is one of the endogenous secretagogues of PRL. In this study, we investigated the effect of cyclo (His-Pro) on the cytosolic Ca2+ concentration [[Ca2+]i) in cultured lactotrophs by using a lactotroph-enriched fraction separated from female rat pituicytes by centrifugal elutriation. TRH (10 nM) induced a rapid rise in [Ca2+]i in the lactotrophs, followed by a plateau phase of prolonged increase in [Ca2+]i. In contrast, the addition of 100 microM of cyclo (His-Pro) caused no changes in the basal level or the TRH-induced plateau response of [Ca2+]i. Although pretreatment with cyclo (His-Pro) tended to decrease the biphasic increase in [Ca2+]i induced by TRH, the inhibitory effect was not statistically significant. These results demonstrated that cyclo (His-Pro) has no effect on [Ca2+]i in lactotrophs, and does not affect the TRH-induced increase in [Ca2+]i, indicating that the inhibition of PRL secretion by cyclo (His-Pro) may be primarily mediated by other intracellular messengers such as cyclic nucleotides and secondarily involved in other inhibitory systems including that of dopamine.

The distribution of Histidyl-Proline Diketopiperazine [cyclo(His-Pro)] in discrete rat hypothalamic nuclei

The distribution of Histidyl-Proline Diketopiperazine [cyclo[His-Pro)], a metabolite of thyrotropin-releasing hormone (TRH), was determined by specific RIA in Palkovits micropunch pools derived from discrete hypothalamic nuclei. Highest concentrations of cyclo(His-Pro) were identified in the anterior nucleus (3.5 ng/mg protein) and the paraventricular nucleus (2.95 ng/mg protein), while lower concentrations of cyclo(His-Pro) were seen in the other 6 nuclei. In contrast, TRH concentrations were highest in the ventromedial nucleus pars medialis (3.2 ng/mg protein) and arcuate nucleus (2.7 ng/mg protein). This qualitatively different distribution of cyclo(His-Pro) from that of TRH suggests that not all of cyclo(His-Pro) is derived exclusively from TRH.

Spontaneous Spiking Activities of Porcine Pars intermedia Cells: Effects of Thyrotropin-Releasing Hormone

The electrophysiological properties of porcine melanotrophs in primary culture were studied with patch clamp techniques. In the cell-attached (c/a) configuration, extracellular spikes were recorded but in only 47 of the 259 cells examined; active cells were more frequently found in short-term cultures (48 h, 22 out of 71). In the whole-cell (WCR) configuration, the mean resting potential was -46.6 mV and the mean input resistance 2.41 G omega. In the current clamp mode, of the 99 cells recorded, 39.4% displayed spontaneous spiking activities, 14.1% spiked when a depolarizing current was applied, and 46.5% were silent. Two patterns of spontaneous activity were recorded. The first consisted of rapid membrane depolarizations (mean duration: 16.0 ms) which reached a mean value of +8.9 mV. These action potentials occurred either at random intervals or at a mean frequency of 1.19 Hz. Tetrodotoxin (TTX), a sodium channel blocker, completely abolished these action potentials. The second pattern consisted of regular bursts (mean duration: 1.69 s and mean frequency: 0.15 Hz) of spikes with smaller amplitudes (culminating at -9.5 mV) and greater durations (79.7 ms). This pattern could be recorded in the presence of TTX in the external medium. In the c/a configuration, thyrotropin-releasing hormone (TRH) and (3Me-His2)-TRH enhanced spike frequency, whereas histidyl-proline-diketopiperazine, a metabolite of TRH, had no effect. In WCR, out of the 27 cells tested, TRH (5.10(-9)-5.10(-8) M) induced firing in 4 quiescent cells and increased the frequency of action potentials in 4 spontaneously active cells. This was usually, but not necessarily, preceded by a hyperpolarization (n = 5). TRH (5.10(-8) M) enhanced the secretion of melanocyte-stimulating hormone (alpha MSH) from perfused isolated melanotrophs by 62.8 +/- 9.8% (n = 9) over basal levels. (3Me-His2)-TRH and (Pro3)-TRH mimicked the TRH response, whereas histidyl-proline-diketopiperazine was without effect.

Re-evaluation of histidyl-proline diketopiperazine [cyclo(his-pro)] effects on food intake in the rat

Histidyl-proline diketopiperazine [cyclo(His-Pro)], a metabolite of thyrotropin releasing hormone, (TRH) has been reported to decrease food intake of rats in a variety of feeding models following intracerebroventricular (ICV) injection. We have re-evaluated the anorectic effects of cyclo(His-Pro) on food deprivation-induced and spontaneous feeding. When injected ICV at the end of the light period into ad lib fed rats, neither the naturally occuring cyclo(L-His-L-Pro) isomer (14 to 1000 nmole/rat) nor any of the four cyclo(D,L-His-D,L-Pro) stereoisomers (100 nmole/rat) significantly suppressed food intake at any hour for up to 12- or 24-hr post-injection. Bombesin (0.6 nmole/rat ICV) decreased food intake in the same model by up to 86% with anorexia still apparent 15-hr post-injection (71%, p<0.001). In two food deprivation-induced feeding models, cyclo(L-His-L-Pro) (100 and 1000 nmole/rat ICV) did not cause anorexia while TRH (10 and 1000 nmole/rat ICV) maximally suppressed food intake by 74% ( p<0.02) and 50% ( p<0.01). Occasional transient increases of food consumption were observed in cyclo(His-Pro)-treated rats during both spontaneous and induced feeding. Cyclo(L-His-L-Pro) was also without effect on food intake when intraperitoneally administered at 12.5 and 30 μmole/kg to schedule fed rats. TRH at 30 μmole/kg IP transiently suppressed food intake of schedule fed rats ( p<0.005). These findings indicate that cyclo(His-Pro) does not exhibit anorectic activity in the rat and cast doubt on the concept that TRH-induced anorexia results from conversion of TRH to an active cyclo(His-Pro) metabolite.

Antinociceptive activity of TRH metabolites in the mouse

The antinociceptive action of the 2 main metabolites of thyrotropin-releasing hormone (TRH), pyroglutamyl-histidyl-proline (TRH-OH) and histidyl-proline-diketopiperazine or cyclo(His-Pro), were studied using mechanical (Haffner's test) and chemical (phenyl- p-benzoquinone writhing test) stimuli. TRH has previously been shown to be active against both these stimuli. TRH-OH showed an antinociceptive action against both stimuli, while cyclo (His-Pro) had a dose-dependent effect only against a mechanical stimulus. Both metabolites of TRH were less effective than TRH. The antinociception induced by TRH does not appear to depend on the biotransformation of TRH to its metabolites since they are less active than TRH itself.

Behavioural and biochemical evidence for the release of noradrenaline in mouse brain by TRH and some of its biologically stable analogues

Small doses of clonidine probably induce hypoactivity (a distinct form of sedation) by stimulating presynaptic α 2-adrenoceptors. This was attenuated by injection of 0.1–10 mg/kg of thyrotropin releasing hormone (TRH) or its biologically stable analogues, CG3509, CG3703 and RX77368, when these were given 10 min before clonidine. This effect was dose-dependent in all cases, but the analogues were more potent than TRH. The TRH metabolites, TRH acid and histidyl-proline diketopiperazine (10 mg/kg) were without effect. This response was still attenuated by the analogues, but not TRH, when these were given 1 hr before clonidine. The results, therefore, suggested that it was the basic tripeptide structure which was active and TRH was less potent than its analogues because of rapid metabolism. Attenuation of hypoaetivity by TRH and analogues was not due to increased dopaminergic function because apomorphine (5mg/kg) was ineffective. Thyrotropin releasing hormone (20mg/kg), CG3509 (10mg/kg) and CG3703 (1mg/kg) also induced locomotor activity and produced various other behavioural changes. This was inhibited by prazosin (3 mg/kg) and haloperidol (0.5 mg/kg) but not by yohimbine (1 mg/kg). Apomorphine (5 mg/kg)-induced activity was inhibited by haloperidol and yohimbine but not by prazosin. This indicated that the activity produced by the TRH compounds, but not apomorphine, was partly mediated by α 1-adrenoceptors. Both CG3509 (10 −5 and 10 −4 M) and RX77368 (10 −4 M) evoked the release of endogenous noradrenaline from slices of hypothalamus in vitro. The TRH analogues, however, had no affinity for α 1- or α 2-adrenoceptors in ligand-receptor binding experiments. Viewed overall, the data showed that TRH and its analogues induced the release of noradrenaline in the brain. In addition, a comparison of the behavioural effects of TRH compounds with dopamine and α 1-adrenoceptor agonists suggested that in mice these behavioural responses resulted from stimulation of both noradrenergic and dopaminergic function.

The involvement of central cholinergic mechanisms in cardiovascular responses to intracerebroventricular and intravenous administration of thyrotropin-releasing hormone

Intracerebroventricular (i.c.v.) administration of thyrotropin-releasing hormone (TRH) in a range from 0.1 to 100 μg induced a dose-related increase in blood pressure in conscious rats, whereas TRH-free acid (TRH-OH) and histidyl-proline diketopiperazine (His-Pro-DKP), metabolites of TRH, did not. The blood pressure responses to intravenous (i.v.) injection of 5mg/Kg TRH were similar to those induced by TRH (i.c.v.). Pretreatment with atropine (50 μg, i.c.v.) significantly reduced the pressor effect of TRH administered through either route. Hemicholinium-3 (50 μg, i.c.v.), an inhibitor of choline uptake, also prevented the increase in blood pressure induced by TRH (10 μg, i.c.v.). These results indicate that both centrally and peripherally administered TRH have pressor effects that are mediated by central cholinergic mechanisms, probably by activating cholinergic neurons.

Amyotrophic lateral sclerosis: thyrotropin-releasing hormone and histidyl proline diketopiperazine in the spinal cord and cerebrospinal fluid.

In spinal cords from seven amyotrophic lateral sclerosis (ALS) patients and four controls, we found no difference in thyrotropin-releasing hormone (TRH) concentration relative to protein content, but there was a reduction per tissue wet weight in ALS. Immunohistochemical localization of TRH in ALS cord was unaltered. Histidyl proline diketopiperazine (HisPro-DKP), a possible metabolite of TRH, was significantly elevated per protein content in ALS. CSF levels of TRH and HisPro-DKP were unchanged. These findings suggest that TRH neurons are not primarily affected in ALS, but TRH and tissue protein are lost together as the disease progresses.

Histidyl-proline, a rapidly degraded metabolite of thyrotropin releasing hormone, has behavioural activity

The effects of intracerebroventricular (ICV) administration of histidyl-proline (His-Pro; 0, 1, 10 and 100 μg/rat), a rapidly degraded metabolite of thyrotropin releasing hormone (TRH), were assessed using three behavioural paradigms. Locomotor activity was significantly increased over 30, but not 90 min following administration of the highest dose. This stimulatory effect was more apparent when naive rats were tested in an open field without any exposure to the apparatus; the effect was attenuated on a second exposure. His-Pro treated subjects also tended to prefer the area near the walls of the apparatus. The effects of the dipeptide on visual perception were studied, using a two-choice task. A low but not high (10, versus 100 μg4/rat) dose of His-Pro increased response switching, but did not affect response repetition, latencis or percent correct performance. The results indicate that His-Pro can alter behaviour by affecting motor output, as well as emotional processes.

Effect of low intravenous doses of TRH, acid-TRH and cyclo(His-Pro) on cerebral and peripheral blood flows.

Local cerebral and peripheral blood flow in conscious and anaesthetized rabbits were investigated with the microsphere method, before and after the i.v. administration of 25 or 50 micrograms kg-1 thyrotropin-releasing hormone (TRH). Before the experiment, the cervical sympathetic chain was sectioned on one side in order to evaluate the possible effect of the sympathetic nerves on cranial and extracranial blood flows. Blood flow was also determined in anaesthetized rabbits before and after the administration of the TRH metabolites cyclo(His-Pro) and acid-TRH and after subsequent administration of 50 micrograms kg-1 TRH. TRH caused an increase in mean arterial blood pressure (MAP) of about 1 to 2 kPa whereas cyclo(His-Pro) and acid-TRH had no effect on MAP. In the anaesthetized animal an increase in total cerebral blood flow (CBFtot), from 71 +/- 7 to 107 +/- 12 g min-1 100 g-1 (P less than 0.05) was observed on the sympathetic intact side after 25 micrograms kg-1 TRH and a further increase to 130 +/- 9 g min-1 100g-1 (P less than 0.01) after 50 micrograms kg-1 TRH. A similar effect was observed on the sympathotomized side. An effect on CBF in the conscious animal was not detected. The control CBFtot (104 +/- 8 g min-1 100g-1) was higher in these animals than in the anaesthetized animals (P less than 0.02). Neither cyclo(His-Pro) nor acid-TRH mimicked the effect of TRH on CBF. In several peripheral tissues, e.g. skin, pancreas and gastric mucosa, a reduction in blood flow was noted after the administration of TRH in both anaesthetized and conscious rabbits. It was concluded that TRH can induce cerebral vasodilatation in animals with a depressed CBF, whereas the vasoconstrictor effect of TRH in peripheral organs is not markedly affected by the state of consciousness.

Lack of interaction between thyrotropin releasing hormone and its analogs with 3H-quinuclidinyl benzilate recognition sites in the rat striatum

The effect of thyrotropin releasing hormone (TRH) on the binding of 3H-quinuclidinyl benzilate (QNB) to cholinergic muscorinic receptors of striatal region of rat brain were evaluated. In vitro studies indicate that neither TRH, its two analogs, MK-771 [ L-N-(2-oxopiperidin-6-yl-carbonyl)-L-histidyl-L-thiazolidine-4-carboximide ] and DN-1417 (γ-butyrolactone-γ-carbonyl-L-histidyl-L-prolineamide) nor the metabolite histidyl-proline diketopiperazine [ cyclo(His-Pro) ] at concentrations ranging from 10 −9 to 10 −3 M affected 3H-(-QNB binding to striatal muscarinic receptors. On the other hand, p-Glu-His-Pro-OH (TRH-free acid), another metabolite of TRH caused significant inhibition (21%) at 10 −4 M concentration. Introperitoneol administration of TRH (I or 10 mg/kg) also failed to ellicit any changes in the affinity (K d) or density (B max) of muscarinic receptors in the striatum. The results suggest that TRH does not influence striotal muscarinic receptors and that the known effects of TRH and its analogs on central cholinergic system may be due to mechanisms other than those affecting postsynaptic muscarinic receptors directly.

Intraventricular administration of cyclo(His-Pro), a metabolite of thyrotropin-releasing hormone (TRH), decreases water intake in the rat.

We explored the effect of cyclo(His-Pro) on drinking in water-deprived rats. Intraventricular administration of cyclo(His-Pro) significantly reduced water intake in these rats in a dose-dependent fashion (3 X 10(-10) -3 X 10(-8) mole), whereas its intraperitoneal injection did not cause any effect on water intake. The inhibitory potency of cyclo(His-Pro) was found to be similar to that of thyrotropin-releasing hormone (TRH), but cyclo(His-Pro) did not significantly interfere with TRH binding in the rat brain. The data indicate that cyclo(His-Pro) action was not mediated through the TRH counterpart. These results suggest that cyclo(His-Pro) may play a potential role in the regulation of water intake in the rat brain.